Advertisement

Topics

FDA Approves IO Combo for Advanced Renal Cell Cancer

11:35 EDT 16 Apr 2018 | Medscape

The approval of the nivolumab and ipilimumab combination provides a new first-line treatment option for a segment of patients with advanced renal cell carcinoma.
News Alerts

Original Article: FDA Approves IO Combo for Advanced Renal Cell Cancer

NEXT ARTICLE

More From BioPortfolio on "FDA Approves IO Combo for Advanced Renal Cell Cancer"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Monoclonal antibodies MAbs
Monoclonal antibodies recognise and attach to specific proteins produced by cells.  Types of monoclonal antibodies used to treat cancer cells: Block cell dividing dividing signals Transport cancer drugs or radiation to cancer cells Tr...

Cancer
  Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...